Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity
Indian Journal of Ophthalmology · 2025
DOI: 10.4103/ijo.ijo_558_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Ophthalmology, 2025. Verfasst von Priya Bajgai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vitreoretinal Services, Nepal Eye Institute, Kathmandu, Nepal. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Intravitreal Injections, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the outcome and ocular adverse events of bedside bilateral sequential intravitreal anti-vascular endothelial growth factor injections for retinopathy of prematurity (ROP) (BBSIR).
Methods
This retrospective interventional study included infants who received BBSIR with a follow-up of at least 1 month. Clinical history, intravitreal injection details, indications, intraoperative and postoperative ocular adverse events, and outcomes were analyzed.
Results
The study cohort included 192 babies (384 eyes) spread over 9 years. The mean gestational age was 30.2 ± 2.6 weeks (28.8–34.1), and the birth weight was 1098.11 ± 271.65 g (650–2000). The indications for BBSIR were as follows: 73.4% (n = 141 infants) were too sick to transfer to an ophthalmic unit, 10.9% (n = 21 infants) due to the parents’ inconvenience of traveling to the ophthalmic center, and 15. 6% (n = 30 infants) due to both reasons. The injections were given by an ROP specialist/ROP-trained ophthalmologist after due parental consent, considering each eye as a fresh eye with separate scrubbing and draping. Light from the head-worn indirect ophthalmoscope served as the source of illumination. The retinopathy was regressing/regressed in 92.4% of babies until the last follow-up. The major ocular complication was cataract in 2 eyes (0.5%). There was no incidence of endophthalmitis till last follow-up (median 5.7 months).
Conclusions
As per this study, BBSIR was observed to be effective and safe if given by those fully trained in the management of ROP. Though the rate of complications like cataract is small, they can pose management challenges and impact vision in a growing child.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vitreoretinal Services, Nepal Eye Institute, Kathmandu, Nepal.
- Anant Bajaj Retina Institute, L V Prasad Eye Institute (Mithu Tulsi Chanrai Campus), Bhubaneswar, Odisha, India.
- Anant Bajaj Retina Institute, Srimati Kannuri Santhamma Centre for Vitreoretinal Diseases, L V Prasad Eye Institute (Kallam Anji Reddy Campus), Hyderabad, Telangana, India.
- Department of Ophthalmology, Srirama Chandra Bhanja Medical College and Hospital, Cuttack, Odisha, India.
- Vitreoretinal Services, Anant Bajaj Retina Institute, L V Prasad Eye Institute (Kode Venkatadri Chowdary Campus), Vijayawada, Andhra Pradesh, India.
- Vitreoretinal Services, Grewal Eye Institute, Chandigarh, India.
Zitieren
APA
Bajgai, P., Satavisa, S., Das, T., Jalali, S., Samanataray, B., Nayak, S., & Padhi, T. R. (2025). Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_558_24
Vancouver
Bajgai P, Satavisa S, Das T, Jalali S, Samanataray B, Nayak S, et al. Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity. Indian Journal of Ophthalmology. 2025. doi:10.4103/ijo.ijo_558_24
BibTeX
@article{Bajgai2025,
author = {Bajgai, Priya and Satavisa, Susree and Das, Taraprasad and Jalali, Subhadra and Samanataray, Balakrushna and Nayak, Sameera and Padhi, Tapas Ranjan},
title = {Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity},
journal = {Indian Journal of Ophthalmology},
year = {2025},
doi = {10.4103/ijo.ijo_558_24}
}
EUVIMED